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TEXT 
Text S1. Multiple imputation 
Risk factor data appeared to be missing at random after adjusting for major confounders (e.g. age, sex, 
diabetes, BMI and blood pressure). Hence, multiple imputation was implemented using the M
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algorithm in the statistical package Stata 13.1, to replace missing values in exposure and risk factor 
variables. Imputation models were estimated separately for men and women and included: 
i) all the baseline covariates used in the main analysis (age, quadratic age, diabetes, smoking, 
systolic blood pressure, total cholesterol, HDL cholesterol, index of multiple deprivation; 
diagnosis of another autoimmune disease);  
ii) prior (between 1 and 4 years before study entry) and post (between 0 and 1 year after study 
entry) averages of continuous covariates in the main analysis;   
iii) baseline, prior and post average measurements of covariates not considered in the main 
analysis (diastolic blood pressure, alcohol intake, white blood cell count, haemoglobin, 
creatinine); 
iv) polymyalgia rheumatica and giant cell arteritis status (no, incident, prevalent); 
v) baseline medications (nonsteroidal anti-inflammatory drugs, immunosuppressant drugs or 
biologic therapy, oral corticosteroids, antiplatelet medication, statins, blood pressure 
lowering medication, low-dose aspirin, loop diuretics, oral contraceptives and hormone 
replacement therapy); 
vi) coexisting medical conditions (hypertension, history of depression, cancer, renal disease, 
liver disease, other autoimmune disorders and chronic obstructive pulmonary disease); 
vii) the Nelson-Aalen hazard and the event status for each of the 12 endpoint analysed2; 
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viii) other baseline information: ethnicity, month of registration, abnormal erythrocyte 
sedimentation rate (binary variable), and number of consultations within 1 year before date 
of entry.  
 
Non-normally distributed variables were log-transformed for imputation and back-exponentiated to 
their original scale for analysis. Ten multiply imputed datasets were generated, and Poisson models 
were fitted to each dataset. Coefficients were combined using Rubin’s rules. The Kolmogorov-
Smirnov test was used to compare the distribution of observed versus imputed log-transformed 
covariates.  
 
 
Reference list 
(1) Royston P, White IR, Multiple imputation by chained equations (MICE): Implementations in 
STATA, Journal of Statistical Software, 2011; 45(4): 1-20. 
(2) van Buuren S. Muliple imputation of discrete and continuous data by fully conditional 
specification. Stat Methods Med Res. 2007; 16: 219-242. 
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TABLES 
Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis 
Read codes Polymyalgia rheumatica 
N20..00    Polymyalgia rheumatica                                   
N20..00    Polymyalgia 
N200.00   Giant cell arteritis with polymyalgia rheumatica                                           
 
Giant cell arteritis 
G755100 Temporal arteritis 
G755000 Cranial arteritis 
G755.00 Giant cell arteritis 
N200.00 Giant cell arteritis with polymyalgia rheumatica 
Nyu4100 [X]Other giant cell arteritis 
G755z00 Giant cell arteritis NOS 
ICD 10 codes 
 Polymyalgia rheumatica 
M353 Polymyalgia rheumatica 
M315 Giant cell arteritis with polymyalgia rheumatica 
 Giant cell arteritis 
M316 Other giant cell arteritis 
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Table S2. List of drugs included as immunosuppressant drugs or biologic therapy 
Azathioprine 
Cyclosporin 
Cyclophosphamide 
Hydroxychloroquine sulphate 
Leflunomide 
Methotrexate 
Rituximab
*
 
 
*Only for patients with giant cell arteritis  
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Table S3. Frequency of recorded supporting information suggestive of polymyalgia rheumatica or giant 
cell arteritis 
 Patients with PMR/GCA 
 N=11,567 
Source of diagnosis  
Diagnosis in CPRD (primary care) 11,420 (98.7) 
Diagnosis in HES (hospital care) 3,189 (27.6) 
Diagnosis in CPRD and HES 3,099 (26.8) 
Receiving care by a rheumatologist within 6 months of 
a recorded diagnosis 
1,453 (12.6) 
Referred to a rheumatologist within 6 months before 
diagnosis 
565 (4.9) 
Medication prescription within 6 months of a recorded 
diagnosis 
390 (33.6) 
Long term use of oral corticosteroids 11,326 (97.9) 
Note: CPRD, the Clinical Practice Research Datalink; GCA, giant cell arteritis; HES, Hospital Episode Statistics; PMR, polymyalgia 
rheumatica. Overall, 85% of patients diagnosed with PMR and/or GCA had supporting information for diagnosis. 
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Table S4. List of diseases considered in the ‘other autoimmune disease’ covariate 
Ankylosis spondylitis 
Autoimmune bullous disease 
Autoimmune uveitis 
Behcet’s disease 
Dermato-polymyositis 
Henoch-Schönlein purpura 
Multiple sclerosis 
Polyarteritis nodosa 
Primary biliary cirrhosis 
Psoriasis 
Rheumatoid arthritis 
Sjögren’s syndrome 
Systemic lupus erythematosus 
Systemic sclerosis          
Wegener’s granulomatosis  
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Table S5. Characteristics* of individuals with and without polymyalgia rheumatica and giant cell 
arteritis 
 Patients with PMR 
and/or GCA 
 (N=11,567) 
Patients without either 
PMR or GCA 
(N=105,504) 
Sociodemographic factors   
Age in years, median [IQR]  73 [65-79] 70 [62-77] 
Women, n (%) 8,392 (72.6) 76,286 (72.3) 
Index of multiple deprivation in quintiles, n (%)   
  1 (least deprived) 2,328 (20.2) 21,062 (20.0) 
  5 (most deprived) 2,265 (19.6) 20,763 (19.8) 
Ethnicity, n (%)   
  White 7,982 (97.7) 62,766 (97.3) 
  Asian 100 (1.2) 768 (1.2) 
  Afro-Caribbean 30 (0.4) 448 (0.7) 
  Other 62 (0.8) 506 (0.8) 
Duration of registration in years, median [IQR] 14.2 [6.6-26.8] 13.4 [6.0-25.3] 
Consultation rate in previous year 10 [6-15] 5 [2-9] 
Autoimmune diseases and inflammation   
Other autoimmune disease, n (%) 1,350 (11.7) 7,116 (6.7) 
Cardiovascular risk factors   
Smoking, n (%)   
  Current 1,023 (9.8) 10,397 (11.4) 
  Former 2,818 (27.0) 22,459 (24.6) 
  Never 6,587 (63.2) 58,584 (64.1) 
Diabetes 777 (6.7) 6,526 (6.2) 
Systolic blood pressure in mmHg, mean (SD) 144 (18.5) 143 (19.0) 
Body mass index in kg/m2, mean (SD)  26.8 (5.1) 26.7 (5.1) 
Total cholesterol in mmol/L, mean (SD)  5.6 (1.2) 5.6 (1.1) 
HDL cholesterol in mmol/L, mean (SD)  1.6 (0.5) 1.5 (0.5) 
Serum creatinine in mg/L, mean (SD) 87.4 (23.9) 88.2 (24.3) 
Medication use in previous year   
Immunosuppressant drugs, n (%) 156 (1.4) 593 (0.6) 
Nonsteroidal anti-inflammatory drugs, n (%) 3,467 (30.0) 14,240 (13.5) 
Oral corticosteroids, n (%) 5,566 (48.1) 2,476 (2.4) 
Antiplatelet therapy, n (%) 1,013 (8.8) 8,787 (8.3) 
Blood pressure lowering medication, n (%) 4,977 (43.0) 38,704 (36.7) 
Statins, n (%) 1,117 (9.7) 9,230 (8.8) 
Note: GCA, giant cell arteritis; HDL, high-density lipoprotein; IQR, interquartile range; PMR, polymyalgia rheumatica; 
SD, standard deviation 
*
Missing data (%): index of multiple deprivation, 0.4%; ethnic group, 37.9%; BMI, 41.8%; systolic blood pressure, 13.0%; 
smoking, 13.0%; total cholesterol, 61.2%; HDL cholesterol, 71.0%; serum creatinine, 47.6%.  
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Table S6. Crude incidence rates of twelve cardiovascular diseases with 95% confidence intervals in individuals with and without polymyalgia 
rheumatica and giant cell arteritis 
 Patients with PMR and/or 
GCA 
(N=11,567) 
 Patients with PMR only 
(N=9,776) 
 Patients with GCA only 
(N=1,164) 
 No. 
events 
Rate / 1000 PY 
(95% CI) 
 No. 
events 
Rate / 1000 PY 
(95% CI) 
 No. 
events 
Rate / 1000 PY 
(95% CI) 
Stable angina 457 8.56 (7.81-9.38)  374 8.33 (7.53-9.22)  56 11.52 (8.86-14.97) 
Unstable angina 101 1.89 (1.56-2.30)  89 1.98 (1.61-2.44)  7 1.44 (0.69-3.02) 
Myocardial infarction 308 5.77 (5.16-6.45)  253 5.64 (4.98-6.38)  39 8.02 (5.86-10.98) 
Unheralded coronary death 170 3.18 (2.74-3.70)  148 3.30 (2.81-3.87)  15 3.09 (1.86-5.12) 
Cardiac arrest 73 1.37 (1.09-1.72)  64 1.43 (1.12-1.82)  2 0.41 (0.10-1.64) 
Heart failure 759 14.21 (13.23-15.26)  619 13.79 (12.75-14.92)  94 19.33 (15.80-23.67) 
Transient ischaemic attack 273 5.11 (4.54-5.75)  216 4.81 (4.21-5.50)  34 6.99 (5.00-9.79) 
Ischaemic stroke 175 3.28 (2.82-3.80)  137 3.05 (2.58-3.61)  30 6.17 (4.31-8.83) 
Subarachnoid haemorrhage 12 0.22 (0.13-0.40)  9 0.20 (0.10-0.39)  2 0.41 (0.10-1.64) 
Intracerebral haemorrhage 54 1.01 (0.77-1.32)  42 0.94 (0.69-1.27)  8 1.65 (0.82-3.29) 
Peripheral arterial disease 297 5.56 (4.96-6.23)  234 5.21 (4.59-5.93)  50 10.28 (7.79-13.57) 
Abdominal aortic aneurysm 108 2.02 (1.67-2.44)  87 1.94 (1.57-2.39)  11 2.26 (1.25-4.09) 
Note: CI, confidence interval; GCA, giant cell arteritis; PMR, polymyalgia rheumatica; Non-disease estimates are obtained among up to 10 randomly selected patients 
without polymyalgia rheumatica or giant cell arteritis matched for sex, age, medical practice and index date; PY, person-years of follow-up; Rates are unadjusted; 
Polymyalgia rheumatica and giant cell arteritis estimates are obtained among patients diagnosed with these diseases who had supporting information for disease diagnosis.  
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Table S7. Crude incidence rate of twelve cardiovascular diseases with 95% confidence intervals in individuals with incident and 
prevalent polymyalgia rheumatica and/or giant cell arteritis 
 Patients without PMR or GCA 
(N=105,504) 
 Patients with incident PMR/GCA 
(N=8238) 
 Patients with prevalent PMR/GCA 
(N=3329) 
 No. 
events 
Rate / 1000 PY 
(95% CI) 
 No. 
event
s 
Rate / 1000 PY 
(95% CI) 
 No. 
event
s 
Rate / 1000 PY 
(95% CI) 
Stable angina 4006 9.55 (9.26-9.85)  258 7.53 (6.66-8.51)  199 10.39 (9.05-11.94) 
Unstable angina 779 1.86 (1.73-1.99)  62 1.81 (1.41-2.32)  39 2.04 (1.49-2.79) 
Myocardial infarction 2112 5.03 (4.82-5.25)  203 5.92 (5.16-6.80)  105 5.48 (4.53-6.64) 
Unheralded coronary death 1516 3.61(3.44-3.80)  83 2.42 (1.95-3.00)  87 4.54 (3.68-5.61) 
Cardiac arrest 511 1.22 (1.12-1.33)  44 1.28 (0.96-1.73)  29 1.51 (1.05-2.18) 
Heart failure 5485 13.07 (12.73-13.42)  423 12.34 (11.22-13.58)  336 17.55 (15.77-19.53) 
Transient ischaemic attack 2356 5.61 (5.39-5.85)  166 4.84 (4.16-5.64)  107 5.59 (4.62-6.75) 
Ischaemic stroke 1425 3.40 (3.22-3.58)  114 3.33 (2.77-4.00)  61 3.19 (2.48-4.09) 
Subarachnoid haemorrhage 139 0.33 (0.28-0.39)  9 0.26 (0.14-0.50)  3 0.16 (0.05-0.49) 
Intracerebral haemorrhage 447 1.07 (0.97-1.17)  27 0.79 (0.54-1.15)  27 1.41 (0.97-2.06) 
Peripheral arterial disease 2107 5.02 (4.81-5.24)  152 4.44 (3.78-5.20)  145 7.57 (6.44-8.91) 
Abdominal aortic aneurysm 676 1.61 (1.49-1.74)   58 1.69 (1.31-2.19)  50 2.61 (1.98-3.45) 
Composite endpoints         
Coronary and CVD death 10,826 25.80 (25.32-26.29)  763 22.26 (20.74-23.90)  528 27.58 (25.32-30.03) 
Fatal and non-fatal CVD  24,372 58.08 (57.36-58.82)  1,736 50.66 (48.33-53.10)  1,276 66.64 (63.08-70.40) 
Note: CI, confidence interval; CVD, cardiovascular disease; GCA, giant cell arteritis; PMR, polymyalgia rheumatica; Non-disease estimates are obtained among up to 10 
randomly selected patients without polymyalgia rheumatica and giant cell arteritis matched for sex, age, medical practice and index date; PY, person-years of follow-up; 
Rates are unadjusted; Incident estimates are obtained among patients diagnosed with polymyalgia rheumatica or giant cell arteritis who had supporting information for 
disease diagnosis and were diagnosed with these diseases at study entry; Prevalent estimates are obtained among patients diagnosed with polymyalgia rheumatica or giant cell 
arteritis who had supporting information for disease diagnosis and had been diagnosed with these diseases before study entryThe coronary and CVD death composite 
endpoint includes: stable angina, myocardial infarction, coronary heart diseases not otherwise specified and any cardiovascular death. The fatal and non-fatal CVD composite 
endpoint additionally includes: transient ischemic attack, peripheral arterial disease, and non-fatal heart failure, ischemic or haemorrhagic stroke.  
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Table S8. Adjusted incidence rate ratios for the association between pure and concomitant PMR and GCA, and the initial presentation 
of cardiovascular diseases 
 Patients with incident 
PMR and/or GCA 
IRR (95%CI) 
Patients with prevalent 
PMR and/or GCA 
IRR (95%CI) 
Patients with 
PMR only 
IRR (95%CI) 
Patients with 
GCA only 
IRR (95%CI) 
Coronary and CVD death composite     
Adjusted for age and sex 0.82 (0.76-0.88) 0.96 (0.88-1.05) 0.86 (0.81-0.91) 1.14 (0.99-1.31) 
+ CVD risk factors 0.88 (0.79-0.98) 0.95 (0.76-1.18) 0.91 (0.83-1.00) 1.13 (0.61-2.09) 
   + other autoimmune disease 0.88 (0.79-0.98) 0.94 (0.75-1.16) 0.91 (0.83-0.99) 1.13 (0.61-2.09) 
+ Exclusion of patients     
    with other autoimmune disease 0.89 (0.79-1.00) 0.92 (0.71-1.19) 0.91 (0.83-1.00) 1.13 (0.61-2.09) 
    ≤6 months of follow-up 0.92 (0.82-1.02) 0.99 (0.78-1.26) 0.91 (0.83-1.00) 1.13 (0.61-2.09) 
   <50 years of age 0.85 (0.78-0.91) 0.99 (0.86-1.14) 0.88 (0.83-0.94) 1.21 (0.78-1.88) 
+ Exclusion of 2yr unexposed follow-up for mixed cases
*
 0.88 (0.79-0.99) 0.91 (0.71-1.18) 0.90 (0.82-0.99) 1.12 (0.60-2.07) 
+ Inclusion of patients with & without SID 0.88 (0.79-0.98) 0.93 (0.75-1.16) 0.91 (0.83-1.00) 1.13 (0.61-2.10) 
+ Inclusion of first presentation of CVD
**
 0.87 (0.79-0.95) 1.03 (0.86-1.22) 0.91 (0.84-0.99) 1.13 (0.68-1.89) 
Fatal and non-fatal CVD composite     
Adjusted for age and sex 0.82 (0.78-0.86) 0.99 (0.94-1.05) 0.86 (0.83-0.90) 1.26 (1.16-1.38) 
+ CVD risk factors 0.85 (0.79-0.91) 0.99 (0.87-1.14) 0.88 (0.83-0.94) 1.21 (0.78-1.87) 
   + other autoimmune disease 0.85 (0.79-0.91) 0.98 (0.85-1.12) 0.88 (0.83-0.94) 1.21 (0.78-1.87) 
+ Exclusion of patients     
    with other autoimmune disease 0.85 (0.78-0.92) 1.02 (0.88-1.19) 0.88 (0.83-0.94) 1.21 (0.78-1.87) 
    ≤6 months of follow-up 0.85 (0.79-0.92) 1.03 (0.90-1.18) 0.88 (0.83-0.94) 1.21 (0.78-1.87) 
   <50 years of age 0.88 (0.79-0.98) 0.94 (0.75-1.18) 0.90 (0.82-0.99) 1.13 (0.61-2.10) 
+ Exclusion of 2yr unexposed follow-up for mixed cases
*
 0.84 (0.78-0.91) 1.01 (0.87-1.18) 0.88 (0.82-0.93) 1.20 (0.77-1.85) 
+ Inclusion of patients with & without SID 0.85 (0.79-0.91) 0.99 (0.86-1.13) 0.88 (0.83-0.94) 1.21 (0.78-1.87) 
+ Inclusion of first presentation of CVD
**
 0.85 (0.79-0.91) 1.00 (0.87-1.15) 0.89 (0.83-0.94) 1.25 (0.83-1.90) 
     
Note: CI, confidence intervals; CVD, cardiovascular disease; GCA, giant cell arteritis; IRR, incidence ratios; PMR, polymyalgia rheumatica; risk factors, cardiovascular 
disease risk factors included index of multiple deprivation, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes; SID, supporting information of disease diagnosis. The coronary and CVD death composite endpoint includes: stable angina, myocardial infarction, coronary heart 
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diseases not otherwise specified and any cardiovascular death. The fatal and non-fatal CVD composite endpoint additionally includes: transient ischemic attack, peripheral 
arterial disease, and non-fatal heart failure, ischemic or haemorrhagic stroke. 
* Censoring of follow-up two years before diagnosis of PMR/GCA for patients who contributed to PMR/GCA and non-PMR/GCA analysis groups (i.e. patients with incident 
disease). 
** Endpoints were the first presentation of the specific cardiovascular disease type regardless of prior occurrence of another type of cardiovascular disease  
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Table S9. Adjusted incidence rate ratios for the association between anti-inflammatory medication use and the initial presentation of 
twelve cardiovascular diseases 
 NSAIDS  
 
 Immunosuppressant drugs 
 All patients 
IRR (95%CI) 
Patients with PMR and/or GCA 
IRR (95%CI) 
 All patients 
IRR (95%CI) 
Patients with PMR and/or GCA 
IRR (95%CI) 
Cardiac diseases      
Stable angina 0.84 (0.72-0.97) 0.85 (0.59-1.22)  0.86 (0.74-1.00) 0.83 (0.58-1.20) 
Unstable angina 0.83 (0.59-1.17) 0.55 (0.34-0.92)  0.87 (0.70-1.21) 0.56 (0.34-0.93) 
Myocardial infarction 1.14 (0.93-1.39) 0.59 (0.44-0.80)  1.15 (0.43-0.59) 0.59 (0.44-0.80) 
Unheralded coronary death 0.76 (0.63-0.92) 0.56 (0.37-0.84)  0.78 (0.65-0.94) 0.55 (0.37-0.82) 
Heart failure 0.97 (0.84-1.12) 1.09 (0.76-1.56)  0.98 (0.85-1.14) 1.08 (0.75-1.55) 
Cardiac arrest 1.04 (0.64-1.68) 1.06 (0.58-1.92)  1.02 (0.63-1.65) 1.06 (0.58-1.92) 
Cerebrovascular diseases      
Transient ischaemic attack 0.66 (0.53-0.82) 0.63 (0.47-0.85)  0.67 (0.54-0.84) 0.63 (0.47-0.86) 
Ischaemic stroke 0.82 (0.63-1.07) 1.16 (0.76-1.79)  0.80 (0.62-1.04) 1.16 (0.75-1.78) 
Subarachnoid haemorrhage 0.23 (0.03-1.69) -  0.28 (0.04-2.14) - 
Intracerebral haemorrhage 0.92 (0.66-1.28) 0.66 (0.34-1.29)  0.92 (0.66-1.28) 0.67 (0.34-1.30) 
Peripheral vascular diseases      
Peripheral arterial disease 0.97 (0.77-1.22) 0.91 (0.57-1.47)  1.02 (0.81-1.28) 0.92 (0.57-1.48) 
Abdominal aortic aneurysm 1.26 (0.91-1.75) 0.41 (0.26-0.67)  1.24 (0.89-1.73) 0.42 (0.26-0.67) 
Composite endpoints      
Coronary and CVD death 0.87 (0.79-0.96) 0.74 (0.65-0.85)  0.89 (0.81-0.98) 0.74 (0.65-0.85) 
Fatal and non-fatal CVD 0.86 (0.811-0.92) 0.81 (0.74-0.89)  0.88 (0.82-0.94) 0.81 (0.74-0.89) 
Note: CI, confidence interval; GCA, giant cell arteritis; IRR, incidence rate ratios adjusted for sex, age, polymyalgia rheumatica and giant cell arteritis diagnosis, index of 
multiple deprivation, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and diabetes; NSAIDS, non-steroidal anti-
inflammatory drugs. Because of the limited number of events in specific clusters, estimates for unheralded coronary death and intracerebral haemorrhage were not adjusted 
for body mass index, systolic blood pressure, total and high-density lipoprotein cholesterol; and no estimates were computed for subarachnoid haemorrhage within the group 
of patients with polymyalgia rheumatica and giant cell arteritis. The coronary and CVD death composite endpoint includes: stable angina, myocardial infarction, coronary 
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heart diseases not otherwise specified and any cardiovascular death. The fatal and non-fatal CVD composite endpoint additionally includes: transient ischemic attack, 
peripheral arterial disease, and non-fatal heart failure, ischemic or haemorrhagic stroke. 
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Table S10. Adjusted incidence rate ratios for the association between pure and 
concomitant PMR and GCA, and the initial presentation of cardiovascular diseases, 
restricted to patients who had evidence of active disease 
 All PMR/GCA 
patients 
PMR/GCA patients with 
active disease 
Coronary & death composite   
PMR only 0.91 (0.83-1.00) 0.90 (0.80-1.01) 
GCA only 1.13 (0.61-2.09) 1.30 (0.59-2.88) 
All GCA 0.67 (0.42-1.07) 0.77 (0.44-1.36) 
PMR and/or GCA 0.90 (0.82-0.98) 0.89 (0.80-1.00) 
Fatal & non-fatal CVD composite   
PMR only 0.88 (0.83-0.94) 0.86 (0.80-0.93) 
GCA only 1.21 (0.78-1.87) 1.41 (0.83-2.41) 
All GCA 0.80 (0.61-1.04) 0.84 (0.59-1.20) 
PMR and/or GCA 0.88 (0.83-0.94) 0.86 (0.80-0.93) 
   
Stable angina 0.86 (0.74-1.01) 0.79 (0.66-0.95) 
Unstable angina 0.86 (0.62-1.20) 0.75 (0.50-1.13) 
Myocardial infarction 1.16 (0.95-1.40) 1.33 (1.07-1.64) 
Unheralded coronary death 0.79 (0.66-0.95) 0.66 (0.50-0.88) 
Heart failure 0.99 (0.85-1.14) 1.00 (0.85-1.17) 
Cardiac arrest 1.03 (0.64-1.67) 1.28 (0.90-1.84) 
Transient ischaemic attack 0.67 (0.54-0.84) 0.71 (0.54-0.94) 
Ischaemic stroke 0.80 (0.62-1.04) 0.76 (0.54-1.06) 
Intracerebral haemorrhage 0.92 (0.66-1.28) 0.72 (0.43-1.19) 
Peripheral arterial disease 1.01 (0.81-1.72) 0.91 (0.69-1.21) 
Abdominal aortic aneurysm 1.24 (0.89-1.72) 1.11 (0.75-1.65) 
Note: Active disease was defined as presence of baseline CRP>3.0 mg/L and/or record of 
elevated or abnormal ESR; GCA, giant cell arteritis; PMR, polymyalgia rheumatica. 
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Table S11. Description of diagnosis codes for patients who were diagnosed with both 
polymyalgia rheumatica and giant cell arteritis (n=627) 
 
 GCA PMR 
Median no. of codes per patient 
(IQR) 
5 (3-10) 5 (3-10) 
Median maximum duration 
between recorded codes in days 
473 (129-1328) 1017 (302-2042) 
Median maximum duration 
between recorded codes (in days) 
among patients who had ≥1 year 
follow-up after each of the initial 
disease diagnosis 
536 (142-1406) 
 
(n=383) 
1055 (336-2082)  
 
(n=426) 
Median maximum duration 
between recorded codes (in days) 
among patients who had ≥2 year 
follow-up after each of the initial 
disease diagnosis 
556 (142-1468) 
 
(n=349) 
1097 (385-2084)  
 
(n=389) 
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Table S12. Adjusted incidence rate ratios for the association between pure and 
concomitant PMR and GCA, and the initial presentation of cardiovascular diseases, 
restricted to patients who had ≥1 diagnosis code recorded after 1 year of the initial 
diagnosis 
 
 Coronary and death 
composite 
Fatal & non-fatal 
CVD composite 
PMR only   
All patients (n=9,776) 0.91 (0.83-1.00) 0.88 (0.83-0.94) 
Including only patients who had ≥1 
diagnosis codes recorded after 1 year 
of the initial diagnosis (n=4,142) 
0.81 (0.69-0.95) 0.86 (0.77-0.95) 
   
GCA only   
All patients (n=1,164) 1.13 (0.61-2.09) 1.21 (0.78-1.87) 
Including only patients who had ≥1 
diagnosis codes recorded after 1 year 
of the initial diagnosis (n=286) 
0.55 (0.07-4.16) 0.96 (0.37-2.50) 
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FIGURES 
Figure S1. Electronic health record phenotyping algorithm for polymyalgia rheumatica 
and giant cell arteritis 
 
 
Note: AI, autoimmune disease; dx code, Read diagnosis code from Clinical Practice Research Datalink (CPRD, 
primary care) or ICD10 code from the Hospital Episode Statistics (HES, hospital); GCA, giant cell arteritis; 
H/O, history of; PMR, polymyalgia rheumatica; SID, supporting information for polymyalgia rheumatica or 
giant cell arteritis diagnosis. Primary analyses only included PMR/GCA patients with supporting information 
for diagnosis. In sensitivity analyses PMR/GCA patients with and without supporting information were 
included. 
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Figure S2. Polymyalgia rheumatica and giant cell arteritis and study definitions 
 
 
 
 
 
1 year       2 years  
    
  
 
 
 
 
Note. GCA, giant cell arteritis; PMR, polymyalgia rheumatica; Patients with prevalent polymyalgia rheumatica 
or giant cell arteritis were those diagnosed prior to the date of eligibility for study inclusion. In combined 
PMR/GCA analyses, study follow-up started on the date of the first recorded diagnosis of the two diseases. 
  
Start non-PMR/GCA follow-up 
Non-disease status 
Start PMR/GCA follow-up 
End non-PMR/GCA follow-up 
PMR/GCA disease status 
End PMR/GCA follow-up 
PMR/GCA diagnosis 
Start PMR/GCA in 
sensitivity analysis 
Eligible for study inclusion 
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Figure S3. Sequential adjustment of incidence rate ratios for the association between 
polymyalgia rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases  
 
 
Note: CI, confidence interval; CVD, cardiovascular disease; CVD medications included use of blood pressure 
and lipid lowering medication; IRR, incidence rate ratios; n, number of events. CVD risk factors included index 
of multiple deprivation, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, 
body mass index and diabetes. Because of the small number of events in specific clusters, estimates for 
unheralded coronary death and intracerebral haemorrhage were not adjusted for body mass index, systolic blood 
pressure, total and high-density lipoprotein cholesterol. Inflammatory medication included immunosuppressant 
drugs and nonsteroidal anti-inflammatory drugs.  
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Figure S4. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases, additionally adjusted for the effect of anti-inflammatory 
medication 
 
Note: CI, confidence interval; IRR, incidence rate ratios; CVD risk factors, cardiovascular risk factors included 
index of multiple deprivation, smoking status, systolic blood pressure, total and high-density lipoprotein 
cholesterol, body mass index and diabetes. Because of the small number of events in specific clusters, estimates 
for unheralded coronary death and intracerebral haemorrhage were not adjusted for body mass index, systolic 
blood pressure, total and high-density lipoprotein cholesterol; n, number of events; NSAIDS, non-steroidal anti-
inflammatory drugs. 
25 
 
Figure S5. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases further adjusted for year of entry  
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, age, index of multiple deprivation, 
smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes. Because of the small number of events in specific clusters, estimates for unheralded coronary death 
were not adjusted for body mass index, systolic blood pressure, total and high-density lipoprotein cholesterol. 
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Figure S6. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases stratified by age group 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, index of multiple deprivation, smoking 
status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and diabetes. 
Because of the small number of events in specific clusters, estimates for unheralded coronary death, 
intracerebral haemorrhage, subarachnoid haemorrhage and cardiac arrest are not adjusted for body mass index, 
systolic blood pressure, total and high-density lipoprotein cholesterol; and no estimates were obtained for 
abdominal aortic aneurysm. 
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Figure S7. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases in men and women 
 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for age, index of multiple deprivation, 
smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes. Because of the small number of events in specific clusters, estimates for unheralded coronary death 
and intracerebral haemorrhage were not adjusted for body mass index, systolic blood pressure, total and high-
density lipoprotein cholesterol; and no estimates were obtained for subarachnoid haemorrhage. 
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Figure S8. Adjusted incidence rate ratios for the initial presentation of cardiovascular 
diseases stratified by disease duration (vs. <1 year duration) among patients with 
polymyalgia rheumatica and/or giant cell arteritis (vs. non-disease)  
 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for index of age, sex, index of multiple 
deprivation, smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass 
index and diabetes. Because of the small number of events in specific clusters, estimates for unheralded 
coronary death, cardiac arrest and intracerebral haemorrhage were not adjusted for body mass index, systolic 
blood pressure, total and high-density lipoprotein cholesterol; and no estimates were obtained for subarachnoid 
haemorrhage. 
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Figure S9. Adjusted incidence rate ratios of the initial presentation of twelve 
cardiovascular diseases for individuals with and without polymyalgia rheumatica, giant 
cell arteritis, or giant cell arteritis regardless of concomitant diagnosis with polymyalgia 
rheumatica (vs. no disease) 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, age, index of multiple deprivation, 
smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes. Because of the small number of events in specific clusters, estimates for unheralded coronary death 
and intracerebral haemorrhage were not adjusted for body mass index, systolic blood pressure, total and high-
density lipoprotein cholesterol. All CGA patients included patients only diagnosed with giant cell arteritis and 
patients with diagnosed both polymyalgia rheumatica and giant cell arteritis. 
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Figure S10. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases from sensitivity analyses. 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, age, index of multiple deprivation, 
smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes. Because of the small number of events in specific clusters, estimates for unheralded coronary death 
and intracerebral haemorrhage were not adjusted for body mass index, systolic blood pressure, total and high-
density lipoprotein cholesterol. Sensitivity analyses were: 
Second row (No other autoimmune disease): Exclusion of patients with a diagnosis of another autoimmune 
disorder. 
Third row (>6 moths of follow-up): Exclusion of patients with less than 6 months of study follow-up. 
Fourth row (2 year follow-up censoring): Exclusion of 2 years of study follow-up before the diagnosis of 
incident PMR/GCA for patients who contributed with follow-up to the PMR/GCA and non-PMR/GCA groups. 
Fifth row (50+ years): Restriction of analysis to patients aged 50 years or older.  
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Figure S11. Comparison of adjusted incidence rate ratios for the association between 
polymyalgia rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases according to disease definition 
 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, age, index of multiple deprivation, 
smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes; SID, supporting information for diagnosis. Because of the small number of events in specific clusters, 
estimates for unheralded coronary death and intracerebral haemorrhage were not adjusted for body mass index, 
systolic blood pressure, total and high-density lipoprotein cholesterol. The SID population included patients 
with polymyalgia rheumatica and giant cell arteritis, who had supporting information of diagnosis and the 
corresponding up to 10 patients without disease matched for age, sex, medical practice and index date. 
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Figure S12. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial presentation of twelve 
cardiovascular diseases before and after the introduction of pay for performance (April 
2004) 
 
 
Note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, age, index of multiple deprivation, 
smoking status, systolic blood pressure, total and high-density lipoprotein cholesterol, body mass index and 
diabetes; QoF, Quality of Outcomes Framework. Because of the small number of events in specific clusters, 
estimates for unheralded coronary death and intracerebral haemorrhage were not adjusted for body mass index, 
systolic blood pressure, total and high-density lipoprotein cholesterol. 
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Figure S13. Adjusted incidence rate ratios for the association between polymyalgia 
rheumatica and/or giant cell arteritis, and the initial and first presentation of twelve 
cardiovascular diseases  
 
 
Note: CI, confidence interval; CVD, cardiovascular disease; IRR, incidence rate ratios adjusted for sex, age, 
index of multiple deprivation, smoking status, systolic blood pressure, total and high-density lipoprotein 
cholesterol, body mass index and diabetes. Because of the small number of events in specific clusters, estimates 
for unheralded coronary death were not adjusted for body mass index, systolic blood pressure, total and high-
density lipoprotein cholesterol. The initial CVD presentation was the first presentation of any cardiovascular 
disease experienced by a patient (e.g. a myocardial infarction for a patient who experienced first a myocardial 
infarction and later developed heart failure). The first event of this type was the first presentation of 
cardiovascular disease for a patient regardless of prior occurrence of another type of cardiovascular disease (e.g. 
a patient who experienced first a myocardial infarction and later heart failure would contribute to both 
myocardial infarction and heart failure estimations). 
 
 
